<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349725</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-502-102</org_study_id>
    <nct_id>NCT01349725</nct_id>
  </id_info>
  <brief_title>A Safety Study of ARRY-502 in Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study, involving a 14-day dosing period, designed to test the safety of
      investigational study drug ARRY-502 in healthy subjects. Approximately 32 healthy subjects
      from the United States will be enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety profile of the study drug as determined by adverse events, clinical laboratory tests, electrocardiograms and vital signs.</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics of the study drug and metabolite as determined by plasma concentrations.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacodynamics of the study drug as determined by laboratory assays.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ARRY-502</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-502</intervention_name>
    <description>Oral; multiple dose, escalating</description>
    <arm_group_label>ARRY-502</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral; matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy male or female between the ages of 18 and 50 years.

          -  Females must be of nonchildbearing potential.

          -  Body mass index (BMI) of 18 to 32 and a total body weight &gt; 50 kg (110 lbs) and &lt; 114
             kg (250 lbs).

          -  Additional criteria exist.

        Key Exclusion Criteria:

          -  Evidence or history of clinically significant disease (excepting allergic rhinitis).

          -  Evidence of hepatitis B, hepatitis C or human immunodeficiency virus (HIV).

          -  Gastrointestinal surgery that may interfere with motility or absorption.

          -  Serious illness requiring hospitalization within the previous 6 months.

          -  A positive test for drugs or alcohol.

          -  Recent use of tobacco- or nicotine-containing products. Use of any medications,
             grapefruit or supplements within the previous 14 days.

          -  Use of corticosteroids within the previous 28 days.

          -  Recent history of blood, plasma or platelet donation.

          -  Treatment with a small-molecule investigational drug within the previous 30 days or
             any biologic therapy within the previous 6 months.

          -  Prior exposure to investigational study drug ARRY-502.

          -  Additional criteria exist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <last_update_submitted>October 19, 2011</last_update_submitted>
  <last_update_submitted_qc>October 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

